2-(4-苄基哌嗪-1-基)噻唑-5-甲醛 | 303987-22-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 2-(4-苄基哌嗪-1-基)噻唑-5-甲醛
• 英文名称: 2-(4-Benzylpiperazino)-1,3-thiazole-5-carbaldehyde
• 英文别名: 2-(4-benzylpiperazin-1-yl)-1,3-thiazole-5-carbaldehyde
• CAS: 303987-22-6
• 化学式: C₁₅H₁₇N₃OS
• 分子量: 287.4
• InChiKey: ICEJWPVGLIEGTK-UHFFFAOYSA-N

物化性质

• 熔点：
  107-109°C
• 溶解度：
  >43.1 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  64.7
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934100090

文献信息

• Alkylidene pyrazolidinedione derivatives
  申请人：——

  公开号：US20040220188A1

  公开（公告）日：2004-11-04

  The present invention is related to the use of alkylidene pyrazolidinedione derivatives of formula (I) for the treatment and/or prevention of diabetes type I and/or II, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity and polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of alkylidene pyrazolidinedione derivatives of formula (I) to modulate, notably to inhibit the activity of PTPs, in particular PTP1B, TC-PTP, SHP and GLEPP-1. The present invention is furthermore related to novel alkylidene pyrazolidinedione derivatives. (I) R1 and R2 represent independently from each other an unsubstituted or substituted aryl or heteroaryl. 1

  本发明涉及使用式(I)的烷基亚甲基吡唑啉二酮衍生物治疗和/或预防糖尿病I型和/或II型、糖耐量受损、胰岛素抵抗、高血糖、肥胖症和多囊卵巢综合症（PCOS）。特别是，本发明涉及使用式(I)的烷基亚甲基吡唑啉二酮衍生物调节，特别是抑制PTPs的活性，尤其是PTP1B、TC-PTP、SHP和GLEPP-1的活性。本发明还涉及新的烷基亚甲基吡唑啉二酮衍生物。(I)中，R1和R2各自独立地表示未取代或取代的芳基或杂环芳基。
• ALKYLIDENE PIRAZOLIDINEDIONE DERIVATIVES AND THEIR USE FOR TREATING DIABETES AND OBESITY
  申请人：Applied Research Systems ARS Holding N.V.

  公开号：EP1399156A2

  公开（公告）日：2004-03-24
• [EN] ALKYLIDENE PYRAZOLIDINEDIONE DERIVATIVES<br/>[FR] DERIVES D'ALKYLIDENE PYRAZOLIDINEDIONE
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2002102359A2

  公开（公告）日：2002-12-27

  The present invention is related to the use of alkylidene pyrazolidinedione derivatives of formula (I) for the treatment and/or prevention of diabetes type I and/or II, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity and polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of alkylidene pyrazolidinedione derivatives of formula (I) to modulate, notably to inhibit the activity of PTPs, in particular PTP1B, TC-PTP, SHP and GLEPP-1. The present invention is furthermore related to novel alkylidene pyrazolidinedione derivatives. (I) R1 and R2 represent independently from each other an unsubstituted or substituted aryl or heteroaryl.